TABLE OF CONTENTS

About Gateway ................................................................. 3
From the Desk of the Chairman ......................................... 4
A Message from the President .......................................... 5
Our Challenge ................................................................. 6
Our Work ........................................................................... 7
Our Partner
Patient Profile: Gordon Kent Thomas ............................. 8
Researcher Spotlight: Charalambos Andreadis, MD, MSCE 9
Patient Profile: Beth Vanderkin ....................................... 10
Signature Event: The Greatest Gateway .......................... 11
Signature Event: Vino con Stelle ..................................... 12
Signature Event: Saint Patrick’s Day Party ....................... 13
Young Investigator Award
Gateway Discovery Grant Program ............................... 14
Gateway Associates Board ............................................. 15
50/50 Fundraising Challenge .......................................... 16
Ways to Give .................................................................. 17
Funded Researchers ......................................................... 19
Thank You to Our Donors .............................................. 20
Board of Directors .......................................................... 30
Board of Scientific Counselors
Research Advisory Committee
Associates Board
Financial Highlights ...................................................... 31
ABOUT GATEWAY

GATEWAY FOR CANCER RESEARCH FUNDS TRANSFORMATIONAL CANCER RESEARCH THAT HELPS PATIENTS FEEL BETTER AND LIVE LONGER, AS WE SEEK TO PUT AN END TO CANCER AS WE KNOW IT. WE PARTNER WITH DEDICATED PHYSICIANS, CLINICIAN-SCIENTISTS AND RENOWNED RESEARCH INSTITUTIONS AROUND THE WORLD TO ADVANCE INNOVATIVE CANCER TREATMENTS AND CURES. ALL OF THIS IS GUIDED BY A CLEAR VISION:

TO CREATE A WORLD IN WHICH A CANCER DIAGNOSIS IS NO LONGER FEARED.
On behalf of patients, families, and physician-researchers around the world, THANK YOU for supporting Gateway for Cancer Research. Your philanthropic investment is making possible some of the world’s most transformational cancer research, ultimately delivering hope and healing to those fighting this insidious disease. It is, of course, because of you that we are paving the way to a world without cancer!

Over the course of nearly three decades, Gateway has filled a vitally important role in the research world. As the go-to funder of Phase I and Phase II clinical trials for all types of cancer, Gateway is on the frontlines of the fight. Early stage, patient-centered studies plant the seeds and pioneer the science that leads to groundbreaking new therapies. In turn, they make measurable, meaningful differences in the lives of cancer patients around the world…NOW!

None of this, however, would be possible without you!

When I founded Gateway in 1991, I knew its mission and vision were critical. I also knew that I wasn’t alone in wanting to create a world in which a cancer diagnosis is no longer feared. The tremendous support Gateway receives from individuals, corporations, and foundations is confirmation of our unique model.

Being a good steward of your gifts is paramount. With underwriting from Cancer Treatment Centers of America® and the Stephenson family, 99 cents of every dollar donated to Gateway directly funds patient-centered clinical cancer research. Everything we do at Gateway is always and only about the patient. Our donors share our commitment to patients and families touched by cancer, and we’re dedicated to managing their investments in a manner that ensures patients are the priority. We hold our grantees to the highest standards when it comes to accountability and reporting on the impact of our donors’ philanthropic investments. We also mandate that therapies that prove effective – even for one patient – must be continued, regardless of whether the study will advance to the next phase or the investigational drug will be manufactured beyond the clinical trial. That’s because at Gateway, clinical research is ruled by a moral code. It’s about doing what’s right – no muss, no fuss, and no fanfare.

Since Gateway’s founding, we have conducted more than 170 clinical cancer trials in collaboration with some of the world’s best and brightest minds in oncology and research – all because of you! Gateway continues to gain momentum, ensuring an even brighter future!

With you, Gateway WILL end cancer as we know it. I can’t think of a more noble endeavor!

With deepest gratitude and appreciation,

Richard J Stephenson
Chairman of the Board
Gateway for Cancer Research
At Gateway for Cancer Research, we fund innovative, early clinical research centered on one objective: to end cancer as we know it. We’re driven by passion, a sense of urgency, and a deep desire to have a lasting impact for the patients we are privileged to serve.

The innovative clinical studies being funded by Gateway around the world are yielding real, tangible results. Make no mistake, patients are being given more options, more time, better quality of life, and the knowledge that they aren’t alone. Through philanthropic contributions from those who believe that ending cancer is a shared responsibility, Gateway is helping patients feel better and live longer.

Traditional funding for clinical trials is limited, and a lack of resources can hinder research and discovery. Gateway opens a whole new world of possibilities. In many ways, we are the gateway that takes novel ideas from the research bench to the patient bedside, turning great ideas into effective new treatments.

Gateway is only as strong as the support it receives from supporters who share our vision. Over the past fiscal year, Gateway received more than $5 million in donations, bringing the number of Phase I and Phase II clinical trials in motion to over 50. The faith shown by those who support Gateway has enabled us to invest more than $85 million in cancer research trials around the world since the organization’s inception in 1991. When it comes to the quest to discover new cancer treatments, Gateway doesn’t just talk the talk. Thanks to you, we most definitely walk the walk.

Within these pages, you’ll learn more about the impact Gateway for Cancer Research has made over the last year. I hope you will be inspired by the breadth and depth of our mission, and you’ll have an even greater understanding of why we must continue to move forward with urgency.

The last year has been filled with many remarkable discoveries and accomplishments. None of it would be possible without you, our forward-thinking and generous donors. On behalf the entire Gateway team and the patients we so passionately serve, thank you for your commitment and your partnership.

Gratefully,

Michael Burton
President and CEO
Gateway for Cancer Research
OUR CHALLENGE

Cancer is a global threat that requires a global response. According to the World Health Organization, more than 18 million people in the world were diagnosed with cancer in 2018. Ending cancer as we know it necessitates the collective drive, dedication, and determination of physicians, scientists, researchers, and philanthropists throughout the world. Bringing to life novel ideas, new therapies, and state-of-the-art treatments is a shared responsibility.

Guided by the clarity of its vision and the generosity of a global philanthropic community, Gateway for Cancer Research funds transformational, breakthrough early phase clinical cancer trials. At the forefront of research and discovery, these trials are the first step in evaluating new cancer medicines, treatments, and therapies. These trials may mark the first-in-human study of a promising drug or therapy.

Despite being critical to advancements in cancer treatment and cures, funding for early phase cancer research is scarce. That’s where Gateway comes in. As a leading funder of Phase I and Phase II cancer clinical trials, Gateway for Cancer Research invests in clinical studies that have the potential to forever change the face of cancer care.

Cancer: A Global Health Threat

- More than 18 million people in the world were diagnosed with cancer in 2018
- There are more than 100 types of cancer
- Cancer accounts for 9.6 million deaths worldwide annually
- Globally, 1 in 6 deaths is attributed to cancer
- In the U.S., more than 1.7 million new cancer diagnoses and more than 600,000 cancer deaths occurred in 2018

"GATEWAY TENDS TO BE IN THE EARLIEST PHASES OF THE STUDY, WHERE THE TRIAL IS VERY EXPLORATORY. SO, IT FITS INTO THAT CRUCIAL PART OF THE ECOSYSTEM OF HOW TO MAKE MEDICINE COME ALIVE – HOW TO MAKE A TREATMENT STRATEGY COME ALIVE. YOU NEED THE ENTIRE ECOSYSTEM TO WORK."

– Siddhartha Mukherjee, MD, DPhil
Gateway-funded researcher and Pulitzer Prize winning author of The Emperor of All Maladies
OUR WORK

Gateway for Cancer Research partners with individuals, corporations, and foundations around the world that understand the importance and are willing to invest in early phase clinical cancer research. Exclusively funding Phase I and Phase II trials for all types of cancer, Gateway is instrumental in bringing to the bedside new cancer treatments and therapies that make a difference for cancer patients of all ages.

Thanks to the generosity of our donors, Gateway has achieved many significant milestones in the quest to shape a world in which a cancer diagnosis is no longer feared.

OUR PARTNER

Cancer Treatment Centers of America® is a national, comprehensive cancer care network established in 1988 by Gateway for Cancer Research founder Richard J Stephenson. CTCA and the Stephenson family generously underwrite Gateway’s operating expenses, ensuring that 99 cents of every dollar Gateway receives goes directly to cancer research.
When Gordon Kent Thomas suddenly started slowing down and experiencing extreme fatigue in late 2017, his family knew something wasn’t right. After months spent explaining away his tiredness as a side effect of working too much, his wife, Deborah, and daughter finally convinced him to see a doctor. What they learned changed their lives.

Kent, as family and friends know him, was in the throes of acute myeloid leukemia (AML), a type of blood cancer that starts in the bone marrow where blood cells are produced. A fairly rare cancer, the American Cancer Society estimates that AML accounts for only about 1% of all cancers.

Kent immediately began chemotherapy, the standard-of-care treatment for AML, which unfortunately was not successful. Kent’s doctors then began exploring other options. That’s when they learned of a Gateway-funded, Phase I clinical trial being conducted by Charalambos Andreadis, MD, MSCE, an oncologist at the University of California, San Francisco. He was evaluating the efficacy of the drug ficlatuzumab used in combination with chemotherapy to treat AML. Kent met the inclusion criteria and was enrolled in the study.

At the time, Kent did not know what a clinical trial was. His wife, Deborah, wasn’t sure the family could afford it. Uncertain of what to do, Kent went to bed one night and prayed for guidance. He woke the next morning, certain that the trial was the right course of action.

Putting their faith in a higher power and trusting the clinical expertise of Dr. Andreadis, Kent began the trial. Within 28 days, his blood tests showed no trace of leukemia. Kent was in complete remission, which meant Kent could undergo a stem cell transplant, the final step in treating his disease.

Today, Kent remains cancer free. He’s home with Deborah, enjoying the life they built together and spending precious time with their children and grandchildren.

A Gateway-funded trial made possible by the generosity of donors around the world gave Kent hope, health, and the healing necessary to enjoy life’s most precious gifts.

---

**PATIENT PROFILE**

**GORDON KENT THOMAS**

---

**ACUTE MYELOID LEUKEMIA (AML)**

- Among the most common types of leukemia in adults
- Accounts for only about 1% of all cancers
- Most common among adults 45 and older
- Roughly 21,450 new cases of AML are diagnosed each year

Source: American Cancer Society
Cure, as we use it today, has the connotation that we’re getting rid of a disease, but really the etymology of the word is from the Latin ‘curare,’ which means to take responsibility for, take care of. In today’s world, I believe somebody who has the time and money to invest in clinical research is actually helping cure patients in the sense that they are taking responsibility for a patient’s life.

– Charalambos Andreadis, MD, MSCE
Gateway-funded researcher and oncologist

RESEARCHER SPOTLIGHT
CHARALAMBOS ANDREADIS
Phase Ib Study: Anti-HGF Antibody with High-Dose Cytarabine in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a cancer of the blood and bone marrow that is characterized by the rapid, chaotic production and spread of abnormal myeloblasts (a type of white blood cell), red blood cells, or platelets. If left untreated, AML spreads quickly, and it can be fatal within a matter of weeks. The standard treatment for AML is remission induction therapy, such as chemotherapy, followed by a stem cell transplant. However, such treatment is not always successful.

Charalambos Andreadis, MD, MSCE, a clinical oncologist specializing in hematological cancer at the University of California, San Francisco, is leading a Gateway-funded clinical trial investigating a new treatment approach for AML.

The investigational study is evaluating efficacy of ficlatuzumab, a monoclonal antibody, used in conjunction with high dose cytarabine, the standard chemotherapy treatment for AML. Ficlatuzumab binds to human hepatocyte growth factor (HGF) and inhibits the HGF/c-Met signaling pathway. This results in cell death in c-Met-expressing tumor cells, such as those present in AML. It is hypothesized that ficlatuzumab increases efficacy of cytarabine, translating to higher clinical response rates and eventual cure in patients with relapsed or refractory disease.

Initial results are promising, with approximately 50% of patients enrolled in the trial achieving complete remission. The trial will advance to Phase II. Based on current study results, Dr. Andreadis is optimistic that the trial will lead to new treatment strategies for this highly lethal disease.

Charalambos Andreadis. CyFi: Results from a phase Ib expansion cohort of ficlatuzumab (Fi) combined with high dose cytarabine (Cy) in patients with high risk relapsed or refractory acute myeloid leukemia (AML). Poster presented at: AACR Annual Meeting 2019; Atlanta, GA.
As a wife and mother of four ranging from middle school to college, Beth Vanderkin’s life was busy, to say the least. In October 2014, life became busier when Beth was diagnosed with diffuse large B-cell non-Hodgkin lymphoma, a blood cancer that originates in a type of white blood cells called lymphocytes.

Following the standard course of treatment for this fast-growing cancer, Beth received chemotherapy. When that was not effective, her doctors attacked the tumor with radiation therapy. While it proved effective in eliminating the tumor, that didn’t mean Beth was in the clear. The only way to truly overcome cancer was through a stem cell transplant.

With funding from Gateway, Nelson Chao, MD at Duke University is testing the idea that stem cell transplant patients could have better outcomes by recovering at home rather than in the hospital setting. The basis for his theory is that a person’s home contains their individual gut microbiome – the bacteria, fungi, and other microbes specific to the person that help control digestion, support the immune system, and benefit other aspect of one’s health. Dr. Chao hypothesized that preserving the microbiome could yield rewards for recovering patients.

“If you live in your home during treatment, you maintain all the bugs that you’re familiar with,” Dr. Chao explained. “Therefore, you’ll have less infections, less complications, better quality of life, and less cost.”

Reflecting on the experience, Beth is grateful to have been able to stay in her home for her treatment. She could sleep in her own bed, celebrate holidays, and spend time with her husband, children, and friends Beth is now enjoying life to its fullest. Knowing her cancer journey would have been drastically different without the clinical trial, Beth is grateful to Dr. Chao for his innovative approach and to Gateway for its willingness to fund a research study that addressed her quality of life while undergoing cancer treatment.

“NEVER AGAIN AM I GOING TO LOOK AT A BIRTHDAY AND SAY, ‘I CAN’T BELIEVE I’M GOING TO BE ANOTHER YEAR OLDER.’ NOW I’M SAYING, ‘I’M SO GLAD I’M GOING TO BE ANOTHER YEAR OLDER!”

– Beth Vanderkin
Gateway Trial Participant

PATIENT PROFILE
BETH VANDERKIN

As a wife and mother of four ranging from middle school to college, Beth Vanderkin’s life was busy, to say the least. In October 2014, life became busier when Beth was diagnosed with diffuse large B-cell non-Hodgkin lymphoma, a blood cancer that originates in a type of white blood cells called lymphocytes.

Following the standard course of treatment for this fast-growing cancer, Beth received chemotherapy. When that was not effective, her doctors attacked the tumor with radiation therapy. While it proved effective in eliminating the tumor, that didn’t mean Beth was in the clear. The only way to truly overcome cancer was through a stem cell transplant.

With funding from Gateway, Nelson Chao, MD at Duke University is testing the idea that stem cell transplant patients could have better outcomes by recovering at home rather than in the hospital setting. The basis for his theory is that a person’s home contains their individual gut microbiome – the bacteria, fungi, and other microbes specific to the person that help control digestion, support the immune system, and benefit other aspect of one’s health. Dr. Chao hypothesized that preserving the microbiome could yield rewards for recovering patients.

“If you live in your home during treatment, you maintain all the bugs that you’re familiar with,” Dr. Chao explained. “Therefore, you’ll have less infections, less complications, better quality of life, and less cost.”

Reflecting on the experience, Beth is grateful to have been able to stay in her home for her treatment. She could sleep in her own bed, celebrate holidays, and spend time with her husband, children, and friends Beth is now enjoying life to its fullest. Knowing her cancer journey would have been drastically different without the clinical trial, Beth is grateful to Dr. Chao for his innovative approach and to Gateway for its willingness to fund a research study that addressed her quality of life while undergoing cancer treatment.

“NEVER AGAIN AM I GOING TO LOOK AT A BIRTHDAY AND SAY, ‘I CAN’T BELIEVE I’M GOING TO BE ANOTHER YEAR OLDER.’ NOW I’M SAYING, ‘I’M SO GLAD I’M GOING TO BE ANOTHER YEAR OLDER!”

– Beth Vanderkin
Gateway Trial Participant

DIFFUSE LARGE B-CELL LYMPHOMA
(DLBCL)

• Most common type of non-Hodgkin lymphoma in the world
• More than 18,000 people diagnosed each year
• Aggressive and fast-growing cancer

Source: Lymphoma Research Foundation

See what Beth and her doctor have to say about how a Gateway-funded clinical cancer trial impacted her treatment at GatewayCR.org/Beth

PATIENT PROFILE
BETH VANDERKIN

As a wife and mother of four ranging from middle school to college, Beth Vanderkin’s life was busy, to say the least. In October 2014, life became busier when Beth was diagnosed with diffuse large B-cell non-Hodgkin lymphoma, a blood cancer that originates in a type of white blood cells called lymphocytes.

Following the standard course of treatment for this fast-growing cancer, Beth received chemotherapy. When that was not effective, her doctors attacked the tumor with radiation therapy. While it proved effective in eliminating the tumor, that didn’t mean Beth was in the clear. The only way to truly overcome cancer was through a stem cell transplant.

With funding from Gateway, Nelson Chao, MD at Duke University is testing the idea that stem cell transplant patients could have better outcomes by recovering at home rather than in the hospital setting. The basis for his theory is that a person’s home contains their individual gut microbiome – the bacteria, fungi, and other microbes specific to the person that help control digestion, support the immune system, and benefit other aspect of one’s health. Dr. Chao hypothesized that preserving the microbiome could yield rewards for recovering patients.

“If you live in your home during treatment, you maintain all the bugs that you’re familiar with,” Dr. Chao explained. “Therefore, you’ll have less infections, less complications, better quality of life, and less cost.”

Reflecting on the experience, Beth is grateful to have been able to stay in her home for her treatment. She could sleep in her own bed, celebrate holidays, and spend time with her husband, children, and friends Beth is now enjoying life to its fullest. Knowing her cancer journey would have been drastically different without the clinical trial, Beth is grateful to Dr. Chao for his innovative approach and to Gateway for its willingness to fund a research study that addressed her quality of life while undergoing cancer treatment.

“NEVER AGAIN AM I GOING TO LOOK AT A BIRTHDAY AND SAY, ‘I CAN’T BELIEVE I’M GOING TO BE ANOTHER YEAR OLDER.’ NOW I’M SAYING, ‘I’M SO GLAD I’M GOING TO BE ANOTHER YEAR OLDER!”

– Beth Vanderkin
Gateway Trial Participant

DIFFUSE LARGE B-CELL LYMPHOMA
(DLBCL)

• Most common type of non-Hodgkin lymphoma in the world
• More than 18,000 people diagnosed each year
• Aggressive and fast-growing cancer

Source: Lymphoma Research Foundation
Unparalleled entertainment and surprises took place “under the big top” at The Greatest Gateway, the 2018 Cures Gala. Inspired by the Oscar-nominated film The Greatest Showman, this incredible evening took place October 20 at the Sheraton Grand Chicago and raised an impressive $4.1 million to fund vitally important clinical cancer research.

More than 700 guests enjoyed engaging musical performances, an exquisite culinary experience, and a high-energy auction – all in the name of funding the future of cancer care.

The night’s mission was brought to life through the story of 13-year-old Peighton Bailey, who participated in a Gateway-funded trial at Children’s Hospital of Los Angeles. Peighton was enrolled in a clinical trial being led by Nathan Robison, MD, a pediatric hematologist-oncologist, using precision medicine to treat low-grade gliomas (brain tumors) with the drug MEK162, an inhibitor in tumor growth pathways. Peighton and her mom Jennifer shared their inspiring story, including how MEK162 shrank Peighton’s brain tumor and how her journey ignited a desire to one day become a doctor and help other children fighting cancer.

Actress and comedian Melissa Peterman served as ringmaster of the star-studded affair, and festivities included performances by R&B sensation Brian McKnight, recording artist Fernando Varela, American Idol finalist Pia Toscano, and 11-year-old America’s Got Talent’s superstar Angelica Hale.

A special thank you to Dr. Stacie J. and Richard J Stephenson for generously hosting The Greatest Gateway Cures Gala!

Major sponsors: Dr. Stacie J. and Richard J Stephenson; Cancer Treatment Centers of America; The Richard Templer Foundation; Andi & Jim Gordon – The Edgewater Funds; International Capital Management Company; International Private Bank; Kenneth C. Griffin Charitable Fund; Katten Muchin Rosenman, LLP; Bob and Cindy Mayo Family Foundation; Rising Tide Foundation; Stellar Insurance, LTD; CliftonLarsonAllen; and McGuireWoods.
The 3rd Annual *Vino con Stelle* was a spectacular evening showcasing “Wines Around the World” on April 12, 2019. Our signature event in Arizona was held inside the impressive Gemini Hangar at the Scottsdale Airpark and raised more than $700,000 to fund patient-centric cancer research.

Actress, TV personality and cancer survivor Brooke Burke served as emcee of the amazing event, and the audience was wowed by performances from Grammy Award winning artist Michael Bolton, world-renowned vocal artists The Tenors and singer songwriter Sheléa.

One of a kind live and silent auctions were a highlight of the evening. Alycia Mondavi, a fourth-generation member of the CK Mondavi and Family winery and CEO of Aloft and Dark Matter Wines, generously donated to the event as a featured vintner, alongside Master Sommelier Alpana Singh. Special guest Cynthia J. Wetmore MD, PhD from Phoenix Children’s Hospital is pursuing promising research to treat diffuse midline glioma, a rare and fatal pediatric brain tumor, and reminded the audience of the importance of clinical trials in the fight against cancer.

From exquisite culinary creations to carefully curated wines from around the world and spectacular entertainment, it was an inspiring evening under the stars showcasing Gateway’s impact in support of life-saving cancer research.

**Presenting sponsors:** Dr. Stacie J. and Richard J Stephenson; Cancer Treatment Centers of America; and IMNA Solutions.
The second *Saint Patrick’s Day Party*, held March 17, 2019 at The Breakers Palm Beach, was a night of festive fare and fun for the sake of funding the future of cancer care. Las Vegas quartet Bella Electric Strings, Sultans of Swing, and Jersey Boys entertained guests.

The *Saint Patrick’s Day Party* was co-chaired by Rebecca Doane and Judi Richards, in memoriam. Its mission and meaning were not lost on guests. Judi Richards, a beloved philanthropist and mainstay in many of Palm Beach’s most noted charitable causes, lost a 13-year battle with lung cancer on her 75th birthday, just two months before the event. Her death was a reminder that the time to end cancer is NOW.

Guests and volunteers who gave their time, talent and treasure for the *Saint Patrick’s Day Party* illustrate the passion, purpose, and possibility that Gateway for Cancer Research gives to those touched by cancer.

**Presenting sponsors:** Dr. Stacie J. and Richard J Stephenson; Cancer Treatment Centers of America

---

**YOUNG INVESTIGATOR AWARD**

Gateway for Cancer Research in partnership with Conquer Cancer named Maria M. Rubinstein, MD, medical oncology fellow at Memorial Sloan Kettering Cancer Center recipient of the 2019 Young Investigator Award. A one-year grant totaling $50,000, this prestigious award provides funding to a promising investigator at the beginning of their career to encourage and promote quality research in clinical oncology.

Dr. Rubinstein’s research focuses on improving outcomes for patients with gynecological malignancies, particularly endometrial cancer. Her trial will be a first-in-human study to evaluate safety, tolerability, and preliminary efficacy of copanlisib (an FDA approved PI3K inhibitor) in combination with a ketogenic diet (KD). This is a novel approach to cancer treatment centered on altering a patient’s diet and metabolism in order to enhance sensitivity to targeted agents, measuring the effectiveness of the combination of copanlisib and a KD on the insulin signaling pathway.

---

**GATEWAY IS PROUD TO RECOGNIZE DR. RUBINSTEIN’S DEDICATION TO THE FIGHT AGAINST CANCER WITH THIS PRESTIGIOUS AWARD. HER PASSION AND COMMITMENT TO PATIENT-CENTRIC RESEARCH AND THE FIELD ARE TRULY AWE-INSPIRING.**

-- Michael J. Burton
President and CEO
Gateway for Cancer Research

Maria M. Rubinstein, MD
2019 recipient of Gateway’s Young Investigator Award
Gateway for Cancer Research launched a new scientific partnership with Conquer Cancer®, the ASCO Foundation to establish the Gateway Discovery Grant Program. This significant grant opportunity awards up to $1.5 million over three years to fund a Phase I or Phase II treatment-based clinical trial that has the potential to impact patient care and advance clinical practice standards for today’s cancer patients. The recipient of the program’s inaugural grant, which is focused on immunotherapy, is being selected in early 2020.

Gateway announced this exciting funding program at its annual reception held in conjunction with the American Society of Clinical Oncology (ASCO®) Annual Meeting on Sunday, June 2 at the Ritz-Carlton Chicago. Gateway welcomed past and current grantees, representatives from major cancer centers, leaders of national cancer research charities, and other industry leaders to learn more about Gateway’s impact and our mission. Featured speakers included Maurie Markman, MD, President of Medicine and Science at Cancer Treatment Centers of America®, Michael J. Burton, President and CEO of Gateway; Cynthia J. Wetmore, MD, PhD, Division Chief of the Center for Cancer and Blood Disorders at Phoenix Children’s Hospital; and Clifford A. Hudis, MD, FACP, FASCO, CEO of ASCO®.

THIS EXCITING NEW PROGRAM...WILL PROVIDE VITAL SUPPORT FOR CANCER RESEARCH THAT IS ESSENTIAL TO MAKING PROGRESS AGAINST CANCER.

– Nancy R. Daly, MS, MPH, Chief Philanthropic Officer, Conquer Cancer
When it comes to making a difference, age is just a number. Since 2013, young professionals throughout the Chicago area have been advancing Gateway’s mission and vision, giving philanthropists of all ages the opportunity take part in the fight against cancer. Known as the Gateway Associates Board, this powerful network of up and coming leaders garners year-round support for Gateway through various volunteer and fundraising efforts.

From annual events like the Derby Day Party and Be A Hero cocktail reception, to a range of smaller fundraising and networking activities, the group makes giving a priority. Over the last year, the Gateway Associates Board raised more than $95,000 to fund transformational clinical cancer trials. Our deepest gratitude extends to all members of the Associates Board for their tremendous support and dedication to Gateway and patients benefiting from lifesaving research around the world.

Keep up with the Gateway Associates Board by following them on social media:

- @gateway_ab
- @GatewayAssociatesBoard

The 5th Annual Be A Hero soirée, held October 12, 2018 at Chez Chicago, was a festive affair, supporting the heroic efforts of cancer researchers and scientists around the world. More than 200 attendees gathered for an evening of delicious food, cocktails, dancing, and bidding.

On May 4, 2019, Gateway Associates Board members and guests gathered at Public House in downtown Chicago for the annual Derby Day Party. This festive afternoon spent cheering on the horses at Churchill Downs raised more than $30,000 – enough to fund more than 1,800 days in a clinical trial.
For Board Member Rhonda Kokot, the reason to support Gateway for Cancer Research is simple – she knows firsthand what it’s like to hear the words “you have cancer” and what it means to participate in a clinical trial. Her path to giving back, however, wasn’t quite as simple.

Rhonda was diagnosed with advanced acute myeloid leukemia (AML) in 2001. She was just 29. Her only treatment option was chemotherapy and radiation followed by a stem cell transplant. In 2002, she began a clinical trial at the University of Minnesota that was studying the use of umbilical cord stem cells to treat AML. The trial was successful for Rhonda and other study participants, resulting in a new standard of care.

“I’m living proof that clinical trials work,” Rhonda said. “Without it, I would not be here today.”

Cancer-free and grateful to be alive and thriving, Rhonda was determined to give back in a uniquely personal and challenging way. Her plan? To complete 50 half marathons (13.1-mile races) in 50 states, soliciting donations along the way. She kicked off the challenge in 2008, running half marathons in Hawaii and Alaska.

Eleven years, 50 half marathons, and 655 miles later, Rhonda completed her 50th and final half-marathon of the challenge in June 2018 in Jackson Hole, Wyoming. Rhonda’s personal challenge turned fundraiser for Gateway surpassed her goal, raising more than $100,000 – enough to fund more than 6,000 days of clinical trial research and make a difference in countless patient lives.

“\"I love the idea that I’m raising these critical funds that will go toward finding more effective and less toxic treatment options. Feels amazing.\"”

– Rhonda Kokot
Cancer Survivor and Gateway Board member
WAYS TO GIVE

There are many ways to support Gateway’s mission to fund meaningful and breakthrough clinical trials worldwide that help people living with cancer to feel better and live longer.

Event Sponsorship
Sponsor the Cures Gala or Vino con Stelle, Gateway’s signature fundraising events, to show your support and help make a meaningful impact the fight against cancer.

Make a Donation
Fund a day, a week, a month, or make a donation in any amount to advance Gateway’s vision of creating a world in which a cancer diagnosis is no longer feared.

Tribute Gifts
Show how much your friend or loved one means to you by making a donation in their honor.

DIY Fundraiser
Gateway provides all the tools and resources you need for a successful event, from bowling parties to walks, runs and bake sales.

In-Kind Gifts
Gifts of merchandise, products, or experiences create excitement at signature events and give you impactful marketing exposure.

Life Insurance
Create an inspirational legacy by naming Gateway as beneficiary of a life insurance policy that you or your family may no longer need.

Stocks
Gifts of stock help continue Gateway’s funding of breakthrough cancer treatments.

Wills and Bequest
Include Gateway in your will or bequest to create a lasting legacy through clinical cancer research.

Charitable Trusts
Establish a charitable trust that enables you and your family to make a difference by directly supporting clinical cancer research.

Corporate Social Responsibility Partner
Gateway’s partners share our passion for helping others and finding meaningful treatments and cures for cancer.

Volunteering
Make a difference through the gift of your time by volunteering at an event or joining a committee – it’s a great way to meet people and have fun while helping to advance Gateway’s mission.

For more information on these ways to give, visit our website at GatewayCR.org or call 888-221-2873.
FUNDED RESEARCHERS

Boston Children’s Hospital
Alexandra Carey, MD

Canadian College of Naturopathic Medicine
Dugald Seely, ND, MSc

Cantonal Hospital
Christoph Mamot, MD

Children’s Hospital Los Angeles
Hisham Abdel-Azim, MD, MS
Nathan Robison, MD
Alan Wayne, MD

Cincinnati Children’s Hospital Medical Center
Stella Davies, MBBS, PhD, MRCP
Parinda Mehta, MD

City of Hope
Christine Brown, PhD
Jeffrey Wong, MD

Cleveland Clinic
Miriam Cremer, MD, MPH
David Levy, MD

Columbia University
Siddhartha Mukherjee, MD, DPhil

Dana-Farber Cancer Institute
Toni Choueiri, MD
Khanh Do, MD
Rachel Freedman, MD, MPH

Duke University
Rachel Blitzblau, MD, PhD
Nelson Chao, MD

Geneva University Hospital
Nicholas Mach, MD

George Mason University
Emanuel F. Petricoin, PhD

International Breast Cancer Study Group
Olivia Pagani, MD

John Theurer Cancer Center at Hackensack University
David Schwartz, MD, PhD

Johns Hopkins University
Nilofer Azad, MD
Lei Zheng, MD, PhD

Karmanos Cancer Institute
Ulka Vaishampayan, MD

Massachusetts General Hospital Cancer Center
David Ting, MD

Mayo Clinic
Charles Loprinzi, MD

The University of Texas MD Anderson Cancer Center
Lorenzo Cohen, PhD
Robert L. Coleman, MD, FACOG, FACS
Amol Ghia, MD
Nancy Gordon, MD
Aung Naing, MD, FACP
Katy Rezvani, MD, PhD
Nizar Tannir, MD, FACP

Memorial Sloan Kettering Cancer Center
Lee Jones, PhD
Dana Rathkopf, MD

The Ohio State University
Maryam Lustberg, MD, MPH

Ottawa Hospital Research Institute
Rebecca Auer, MD, MSc, FRCSC

Phoenix Children’s Hospital
Cynthia J. Wetmore, MD

Royal College of Surgeons
Bryan Hennessy, MD

Rutgers, The State University of New Jersey
Isaac Kim, MD, PhD, MBA
Janice Mehnert, MD

Seattle Children’s Hospital
Sarah Leary, MD

Sheba Medical Center
Yaakov Lawrence, MA, MBBS, MRCP

St. Jude Children’s Research Hospital
Michael Bishop, MD
Tanja Gruber, MD, PhD
Jeffrey Rubnitz, MD, PhD

Tel Aviv University
Rina Rosin-Arbesfeld, MD

UCLA Jonsson Comprehensive Cancer Center
Richard Pietras, MD, PhD

University Hospital Basel
Sacha Rothschild, MD, PhD

University Hospital, Inselspital
Adrian Ochsenbein, MD

University of Alabama at Birmingham
James Markert, MD, MPH

University of California, San Francisco
Charalambos Andreadis, MD, MSCE
Sabine Mueller, MD, PhD

University of Florida
Christopher Cogle, MD

University of Iowa
Bryan Allen, MD, PhD

University of Texas Southwestern Medical Center
Muhammad Beg, MD
David Gerber, MD

University of Utah
Anupam Verma, MD

Washington University
Rebecca Aft, MD, PhD

The Wistar Institute
Dario Altieri, MD

Yale Cancer Center
Patricia LoRusso, DO
THANK YOU TO OUR DONORS

On behalf of the patients, families, and clinician-scientists around the world for whom your donations are making a difference, thank you for supporting Gateway for Cancer Research and the quest to create a world in which a cancer diagnosis is no longer feared.

Every donor and every dollar make a meaningful difference in the fight against cancer. Your generosity is making possible some of the most innovative, transformational clinical trials that will end cancer as we know it.

### CHAIRMAN’S CIRCLE
**$100,000 and Above**
- Mr. Richard J and Dr. Stacie J. Stephenson
- Cancer Treatment Centers of America
- Clune Construction Company
- Andi and Jim Gordon – The Edgewater Funds
- Mr. and Mrs. Arthur Falcone
- IMNA Solutions, Inc.
- International Capital & Management Company
- Satter Foundation
- Templer Family Foundation

### VISIONARIES CIRCLE
**$50,000 - $99,999**
- CTCA Atlanta
- CTCA Chicago
- CTCA Philadelphia
- CTCA Phoenix
- CTCA Tulsa
- Ms. Mary Gerdts
- Kenneth C. Griffin Charitable Fund
- Mr. and Mrs. Darren P. Keller
- Marsh Management Services
- ONEHOPE
- Rising Tide
- Miss Shelby Stephenson

### CIRCLE OF IMPACT
**$25,000 - $49,999**
- Allstate Insurance Company
- AmerisourceBergen
- CliftonLarsonAllen, LLP
- Bryan Cressey and Iliana Sweis Cressey Foundation
- Mr. and Mrs. Timothy J. Danis
- Mr. and Mrs. Kent Dauten
- Mr. and Mrs. Larry Day
- Ms. Kimberly T. Duchossois
- The Greg and Anna Brown Family Fund
- Ms. Mellody Hobson
- Mr. and Mrs. Timothy Hostetler and Mrs. Annie Stephenson Hostetler

### CIRCLE OF INNOVATION
**$10,000 - $24,999**
- Abbvie, Inc.
- Allscripts
- Arizona Diamondbacks
- Arizona Public Services
- Mr. and Mrs. Charles Bartels
- The Bill Bass Foundation
- BLG Capital Advisors
- Bluhm Family Charitable Foundation
- Brown Legacy Group
- Mr. and Mrs. Michael Burton
- Canadian Orthodontic Partners
- The Canning Foundation
- Celebrity Fight Night Foundation, Inc.
- CIBC
- Community Outreach Foundation of the Inland Empire
- Deloitte Tax LLP
- Dermatologists of Central States
- Edward & Bethel Kean Charitable Foundation
- Mr. and Mrs. James Eller
- Mr. and Mrs. Michael Entzminger
- Mr. and Mrs. Timothy Flanigan
- Mr. and Mrs. Jay Foley

### CIRCLE OF INNOVATION
**$10,000 - $24,999**
- Mr. and Mrs. Doug Fougnes
- Ms. Connie Frankino
- Goldman Sachs & Company
- Mr. and Mrs. Robert Gould
- Mr. John Graham
- Mr. and Mrs. James Grogan
- Harbour Group Investments
- Mr. and Mrs. Charles Harris
- Mr. and Mrs. Jim Hebets
- Ms. Nancy Hesse
- IBM Watson Imaging
- Insight Enterprises, Inc.
- The International Society Palm Beach
- ITW
- Dr. and Mrs. William Jacobsen
- JN Jewels, LLC
- Mr. and Mrs. Scott E. Jones
- The Kelly Foundation
- Laser Spine Institute
- Litchfield Advisors Incorporated
- Maxor National Pharmacy Services
- McDermott Will & Emery
- Ms. Anne Meisner
- Merkle Health
- The Michael and Meeghan Nemeroff Charitable Fund
- Mr. Adesh Ramchandran and Mrs. Sonia Sahai
- Mr. and Mrs. Tom Reahard
- Dr. and Mrs. Remus Repta
- Riley Construction Company, Inc.
- Mr. and Mrs. William Sasso
- Mr. and Mrs. David Scheible
- Mr. and Mrs. Horst Schulze
- Sheridan Capital Partners
- Spend Mend
- Talent + Inc.
- Drs. Bradford and Ailyn Tan
- Mr. and Mrs. George Terwilliger III
- Tesaro
Mr. and Mrs. Barry Uphoff
Vedder Price PC
Mr. and Mrs. Alan Wilson
Wisconsin Diagnostic
Mr. and Mrs. Larry Wofford
Mr. and Mrs. Michael Wozniak
Dr. and Mrs. Peter Yesawich
Mr. and Mrs. Peter Abuls
Aetna Foundation, Inc.
Mr. Jeffrey Alderton
Ms. Gemma Allen
Ms. Marie Allen
American Heritage Life Insurance Company
Mr. and Mrs. Brad Anderson
APCO Worldwide
Athen Real Estate Group, Inc.
Dr. Peter Baik
Bank of America Merrill Lynch
Ms. Gloria V. Barnes
Mrs. Jennifer Barnett-Sarpalus
Mr. Michael Barr
Mr. and Mrs. Robert Bartels
Mr. and Mrs. Joel Barthelemy
Dr. Nga Basile
Dr. Anderson Bauer
Ms. Lori Beard
Mr. Saby Behar
Mr. Arthur Benjamin
Mr. and Mrs. Karl Berens
Ms. Judith Block Bergman
Mr. and Mrs. Jonathan Bitton
Mr. Frank Bisceglie
Mr. Thomas Blake
Dr. and Mrs. Robert Bloom
BMO Harris Bank
Mr. and Mrs. Michael Bond
Mr. and Mrs. Pierre Bongard
Mr. Elijah Boruchowitz
Ms. Tina Bova
Mr. Adam Brandon
Mr. Donald Brandt
Mrs. Deanna Brant
Mr. and Mrs. Fred Brewer
Dr. C. Komen Brown
Dr. and Mrs. John Brown
Mr. and Mrs. Gordon Burrr
Mr. Andrew Caldwell
Mr. William Caldwell
Mr. Kirk Callwood
Cameo Foundation Fund
CancerSucks, Inc.
Ms. Heide Carlson
Dr. Sean Cavanaugh
CBRE
Mrs. Stella Centeno
Dr. and Mrs. Sung K. Chang
Chicago Association of Realtors
Dr. Robert Childress and Ms. Arlene Busch
Dr. and Mrs. Jeffrey T. Choh
Mr. and Mrs. Larry Christensen
Dr. Young Chung
Mr. and Mrs. Nicholas Ciani
Mr. and Mrs. Joey Ciolli
Citi Private Bank
Civilian
Ms. Janice Applegate Clarke
Mr. Michael Cohen
Ms. Natalie Corrigan
Dr. Randall Craft
Dr. Pamela Crilley
Crossfit PHX, LLC
CTC Trading Group, LLC
Ms. Zalenda Cyrille
Ms. Amalia Dacomas
Mr. Scott Dahlstrom
Ms. Nancy Daly
Dr. and Mrs. George Daneker
Ms. MaryClaire Dangel-Palmer
Mr. and Mrs. Bob Davis
Ms. Susan Denton
Mr. Michael DiCosola
Digital Realty
Mr. and Mrs. Zachary Doehla
Mr. and Mrs. Robert Dowler
Mr. Daniel Duffy
Mr. Gregory Dupuis
Eastling Management
Mr. and Mrs. Bill Eckholm
Mr. Scott Elphinstone
Mr. and Mrs. Louis Feher
Mr. Jay Ferraro and Ms. Liseth Lambright
Mr. and Mrs. Tony Festa
Mr. and Mrs. Roderic Fink
Mr. Dan Fisk
Mr. Paul Furlinger
Mr. Ira Gaines & Mrs. Cheryl Hintzen-Gaines
Dr. Robin Ganzert
Mr. Tanya Gardner
Ms. Carol Brooker-Gardner
Mr. and Mrs. Andy Gilroy
Mr. Robert Glen and Mrs. Margie Roman
Mr. Tom Goede
Ms. Melanie Gomez
Mr. and Mrs. Pete Govorcin
Mr. Matthew Gray
Mr. Richard Grego
Dr. Hatem Halabi
Mr. Roy Hall
Mr. and Mrs. Andrew Hammar
Ms. Dru Hammer
Mr. Scott Hansbury
Ms. Caroline Harless
Mr. and Mrs. Barry A. Hartstein
Ms. Dana Haynes
Mr. and Mrs. Thomas Hayward
Mr. & Mrs. David Hedges
Ms. Charlotte Hendrickson
Mr. Wally Henkel
Henry B. & Jessie W. Keiser Foundation, Inc.
Dr. and Mrs. Jeffrey Hoag
Mrs. Tammi Holden
Ms. Kelly House
Mr. Jim Howard
Mr. and Mrs. C.A. Howlett
Mr. and Mrs. William Hubble
Mr. David Huey
Irvin Saltzman Family Foundation
Jackson Family Foundation
JLL
Dr. and Mrs. Bill Johnson
Dr. Anita Johnson
Ms. Rosemary Jones
Dr. Toufic Kachaamy
Ms. Mindy Kallsnick
Klatskin-Sutker Family Charitable Fund
Mr. and Mrs. Tyler Kane
Dr. Solomon Katta and Mrs. Sindhu Kuruvilla
Katy and Jeffrey Podjasek Charitable Fund
Mr. and Mrs. David C. Kent
Mr. Dennis E. Kepler
Ms. Elana Kipp
Mrs. Eileen Kleinfeldt
Ms. Nichole Knight
Ms. Rhonda Kokot and Mr. Ryan Karvola
Ms. Allison Krivatch
Mr. Steven L. Kroll and Ms. Jenny R. Patterson
Mr. Patrick Kullmann
Mr. Ted Lamb
Mr. and Mrs. Bob LaSarge
Mr. Anderson Laureano
Mr. David Lauschke
CIRCLE OF FRIENDS
$100 - $999
Dr. Elham Abboud
Ms. Gerrick Adams
Adele Anesthesia PC
Mr. and Mrs. Stephen Ahrens
Dr. Sramila Aithal
Ms. Sarah Aitken
Mrs. LaDon Albertson
Mr. Jonathan Alde
Ms. Pamela Alden
Mr. and Mrs. Anthony Alderete
Ms. Roxana Aleksiz
Mr. Arshad Allauddin
Mr. Andrew Allen
Ms. Mailyn Almirante
Mr. and Mrs. Mycal Anders
Mrs. Erin Anderson
Ms. Nicole Andree
Mrs. Jo Ann Andrews
Ms. Kristie Andrews
Mr. Ryan Ansel
Mr. Eric Applegate
Ms. Alaina Argianas
Ms. Kaylee Arteaga
Ms. Adelina Assani-Uva
Mr. and Mrs. Michael Austin
Mr. Mike Averill
Ms. Susan Avila
Mr. and Ms. Mark Axe
Ms. Juliana Baer
Ms. Jeannine Bailey
Mr. and Mrs. Mark Bailey
Mr. Shawn Bala
Mr. Christopher Baldwin
Dr. Frank Balis
Barks Family Foundation
Barrington Saddler
Mrs. Carol Marie Bartlett
Ms. Tara Bartley
Ms. Julie Barton
Mr. & Mrs. Wayne Bauer
Ms. Elizabeth Bausch
Mr. Logan Beall
Mrs. Corey Beam
Mr. and Mrs. Richard P. Benedetto
Ms. Kelly Bennett
Ms. Jen Bergson
Mr. Arnold I. Bertram
Mr. and Mrs. Leslie Beyer
Ms. Ananth Bhogaraju
Mr. Christopher Biggs
Birdsong Electric, Inc.
Mrs. Kathy Blahunka
Ms. Lindsey Blankenship
Ms. Rosemary Bock
Bonnie's Chic Boutique
Mr. Randy Bosman
Ms. Marion Bossle
Mr. John Boswell
Ms. Anne-Marie Boyce
Ms. Jeannette Brauchli
Mr. and Mrs. Sean Brennan
Ms. Darcy Bretz
Mr. Aaron Brooks
Mrs. Jennifer Brown
Ms. Erica Brownlee
Ms. Cristen Brutzus
Mr. Tyler Buck
Ms. Hanh Bui
Mr. Albert Buonamici
Mr. Ethan Burgard
Ms. Elizabeth Burgess
Ms. Alaina Butler
Ms. Monica Cabrera
Ms. Laura C. Camarda
Mr. Pepi Camerlingo
Mr. Daniel Cameron
Ms. Chris Campbell
Mr. and Mrs. Victor Caricato
Mr. Ricardo Carrillo
Dr. James Carter
Dr. and Mrs. Steven Carter
Ms. Nicole Cartuccio
Mr. and Mrs. Paul Casolo
Mr. Aaron Cates
Mr. and Mrs. Ken Chaplin
Ms. Pamela Chapman
Mrs. Tammy Chappell
Ms. Laurel Charles
Ms. Elizabeth Chaviano
Ms. Melanie Chesney
Choice Carrier Corp
Mr. Phillip Chrysler and
Mrs. Angela Loehr Chrysler
Dr. Young Chung
Ms. Janet Cocchiarella
Mr. & Mrs. Cary Cochrane
Mrs. Karen Cole
Mr. and Mrs. William Connelly
Mr. Christopher Connors
Ms. Maude Cook
Ms. Joanne Copas
Mr. Patrick Costanzo
Mrs. Margaret Cotner
Mr. and Mrs. Fred A. Cottini
Ms. Kelly Couch
Council 2
Coyle Brothers Construction Co.
Mr. Matt Crawford
Ms. Jennie Crismore
Ms. Kimberly A. Crown
Ms. Valerie Culling
Mr. Gerald D Culpepper, Jr.
Mr. Anthony Curatolo
Mr. and Mrs. Daniel Cusack
Mr. & Mrs. John Cusack
Mr. Eric Daluga
Mr. Matthew Daneker
Dr. Michael Darby
Ms. Madeline Dardanes
Mr. Robert David
Deason Enterprises, LLC
Mr. and Mrs. Dave L. Deason
Mr. Peter Deckman
Ms. Sandra DeGazarian
Ms. Marie DeGraeve
Mr. Hal DeGrange
Ms. Jamie Delavan
Deli Time
Ms. Jillian Delsignore
Mrs. Lauretta DeMarr
Mrs. Catherine Denny
Mr. Mark Depasquale
Mr. Donald DeVille
Mr. and Mrs. Richard Devoll
Mr. and Mrs. Robert Dick
Mr. and Mrs. Richard Dickson
Mr. Joseph Domanico
Ms. Robin Domogala
Ms. Susan Doran
Ms. Leslie Dorsey
Ms. Samantha Doud
Ms. Ann Douma
Mr. Claire Bolduc Ducharme
Mr. Bryant Duffek
Mr. Scott Dugan
Mr. Zach Dulla
Mr. Richard Dufil
Ms. Gina Eaves
Mr. Eric Eckeman
Richard J and Dr. Stacie J. Stephenson, Gateway Chairman and Vice-Chair, visiting with Gateway-funded researcher Dr. Cynthia J. Wetmore at Phoenix Children’s Hospital
Ms. Kelly King
Ms. Amanda Kinley
Ms. Joany Kircher
Graziella and Patricia Klauss
Mrs. Allison Klimek
Ms. Cinithia Klinger
Mr. Sean Knipe
Ms. Rosemary Koehler
Mr. Ilya Koffman
Mr. Andrew Kogan
Mr. Jerome Kohne
Mrs. Donna Kokot
Mr. Robert Kokot
Ms. Sheri Kokot
Mr. Eucene Komo
Mr. Nicholas Koopaslethes
Mr. Bryan Kortis
Mr. Dave Kotula
Mr. Sam Kubek
Mr. and Mrs. Gary Kulbieda
Ms. Muthu Kuttappan
Mr. and Mrs. Bill Laing
Mr. Darrin Lampman
Mr. Patrick LaPella
Ms. Lynda Lapp
Mr. and Mrs. Giuseppe Laricchia
Mr. Andrew Larson
Mr. John Lavalliere
Ms. Amanda Lavoie
Law Office of Mark G. Vanecko
Ms. Lois Leaburn
Mr. Jeremy Leber
Mr. Mats Lederhausen
Mr. Connor Lee
Mr. Jeffrey Lee
Ms. Frances LeMay
Ms. Kay Lemen
Ms. Amber Lenstrom
Mr. and Mrs. Clifford Levy
Ms. Adrianne Lewis
Ms. Rita Lewis
Mr. and Mrs. Robert D. Libit
Ms. Rany Lierz
Mr. Andrew Limpic
Mr. and Mrs. Ray Lindsay
Ms. Michelle Lindsay
Mr. Michael Lianto
Mr. Lawrence Lloyd
LOL Chicago LLC
Ms. Kristi Long
Ms. Susan Losurdo
Mr. Ron Louiselle
Mr. Carl Loutzenheiser
Ms. Kathleen Love
Mrs. Melissa Lugo
Ms. Denise Lundy
Mr. Sean Lyman
Mr. Brian Lynch
Mr. Kevin Mack
Ms. Teresa Maddox
Mr. & Mrs. Chester Mahan
Ms. Agnes Maia
Mrs. Brea Malloy
Mr. Michael Manion
Mr. Kerr Manson and Mrs. Deniz Razon
Ms. Teresa Markus
Ms. Cathy T. Marquez
Mrs. Jami Marten
Ms. Andy Martinez
Mr. Ronald Martino
Mr. and Mrs. Scott A. Maskalunas
Mr. and Mrs. Richard J. Matzke
Ms. Caroline Maude
Ms. Donna Mayne
Ms. DeAnne McBee
Ms. Kathleen P. McAuliffe
McBride, Lock & Associates, LLC
Ms. Jessica McCambridge
Mr. Edward McCann
Ms. Judy McCorvey
Ms. Maureen McFadden
Mrs. Belinda McDonald
Mr. and Mrs. William F. McKeown
Ms. Stephany McLaughlin
Mr. and Mrs. Dennis J. McNamee
Mr. James McNitt
Ms. Maggie McNulty
Ms. Stephanie Mead
Ms. Christine Medrano
Ms. Toni Meehan
Mrs. Darlene Meese
Mr. Ashish Mehta
Ms. Shelly Meleski
Mr. and Mrs. Melvin Merrill
Mrs. Christine Michaels
Mr. Shane Michelsen
Mr. Dragan Micic
Mr. Vardan Micic
Ms. Sheryl Mooney
Ms. Lorna Moore
Mr. Richard Mooney
Mrs. Amy Moore
Ms. Donna Moccio
Mr. George Molnar
Ms. Colleen Monahan
Ms. Gloria Monarrez
Mr. and Mrs. Kenneth Monarrez
Ms. Victoria Moncello
Mr. Ivan Montes
Ms. Loie Montgomery
Ms. Lorren Moore
Ms. Theresi Morales
Ms. Dina Morgan
Miss Evelyn Morgan
Mr. Rod Morganstein
Ms. Megan Morris
Mr. Tim Morris
Mrs. Jan Morrison-Hein
Mr. Daniel Morton
Ms. Katie Morton
Mr. Ray Moyer
Mrs. Marisa Mulh
Ms. Dawn Mullaney
Ms. Barbara Muller
Ms. Claudia Muriel
Ms. Colleen Murillo
Mr. and Mrs. James Murphy
Mr. Anthony Musso
Mr. and Mrs. Michael Myers
Mr. and Mrs. Paul Nachowicz
Mr. Anthony Nagy
Mr. Salman Naqvi
Mr. Lonnie Nefouse
Mrs. Lauren Nelson
Mr. and Mrs. Brent Nerguizian
Ms. Jennifer Oakley
Ms. Kathleen O'Brien
Mr. and Mrs. Daniel T. O'Conor
Ms. Maureen O'Conor
Mr. and Mrs. Sean O'Conor
Ms. Sara O'Meara
Mr. Winston Orcutt
Ms. Shannon Oscar
Mrs. Jaxon Oshita
Mr. Brian Oswald
Mr. Allen Overeem
Mr. Marc Owen
Mr. and Mrs. Donald Paciorkowski
Ms. Michele Mingee
Mr. and Mrs. Antonio Missanelli
Mr. Duane Mitchell
Mr. Richard Mitchell
Ms. Donna Mo
Ms. Melissa Mobile
Ms. Donna Moccio
Ms. George Molnar
Ms. Colleen Monahan
Ms. Gloria Monarrez
Mr. and Mrs. Kenneth Monarrez
These donations represent cash gifts from July 1, 2018 through June 30, 2019. Gateway has made every attempt to include and highlight the generosity of our donors. If your name is not included on this list and you made a donation of $100 and above, please let us know.
# Financial Highlights

## Fundraising Revenue

<table>
<thead>
<tr>
<th>Source</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contributions</td>
<td>$738,406</td>
</tr>
<tr>
<td>Special Events</td>
<td>$4,783,973</td>
</tr>
<tr>
<td><strong>Total Fundraising Revenue</strong></td>
<td><strong>$5,522,379</strong></td>
</tr>
</tbody>
</table>

## Research Grants

<table>
<thead>
<tr>
<th>Grant Funds</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Awarded</td>
<td>$3,069,665</td>
</tr>
</tbody>
</table>

## Assets

<table>
<thead>
<tr>
<th>Asset</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cash and Cash Equivalent</td>
<td>$3,237,018</td>
</tr>
<tr>
<td>Pledges and Other Receivables</td>
<td>$1,457,291</td>
</tr>
<tr>
<td>Investments</td>
<td>$11,143,958</td>
</tr>
<tr>
<td>Prepaid Expenses</td>
<td>$50,000</td>
</tr>
<tr>
<td>Interests in Limited Partnerships</td>
<td>$8,350</td>
</tr>
<tr>
<td><strong>Total Assets</strong></td>
<td><strong>$15,896,617</strong></td>
</tr>
</tbody>
</table>

## Liabilities

<table>
<thead>
<tr>
<th>Liability</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Accrued Grants</td>
<td>$9,339,348</td>
</tr>
<tr>
<td>Deferred Revenue</td>
<td>$2,915</td>
</tr>
<tr>
<td><strong>Total Liabilities</strong></td>
<td><strong>$9,342,263</strong></td>
</tr>
</tbody>
</table>

## Net Assets

<table>
<thead>
<tr>
<th>Asset</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Net Assets</td>
<td>$6,554,354</td>
</tr>
</tbody>
</table>

| **Total Liabilities and Net Assets** | **$15,896,617** |

*Audited financial statements are available at GatewayCR.org or by request.*